Results 241 to 250 of about 101,444 (326)

VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation

, 2012
Andrea Mencarelli, Sabrina Cipriani, Barbara Renga, Angela Bruno, Claudio D’Amore, Eleonora Distrutti, Stefano Fiorucci   +6 more
openalex   +2 more sources

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

Importance of Setting Reference Ranges for Serum Lipids by Age or Pubertal Stage in Children and Adolescents. [PDF]

J Atheroscler Thromb
Kikuchi T.
europepmc   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source

The impact of overweight on lipid phenotype in different forms of dyslipidemia: a retrospective cohort study. [PDF]

J Endocrinol Invest
Formisano E, Proietti E, Borgarelli C, Sukkar SG, Albertelli M, Boschetti M, Pisciotta L.   +6 more
europepmc   +1 more source

Targeted Next‐Generation Sequencing of the Leptin‐Melanocortin Pathway in Severe Obesity

Obesity, EarlyView.
ABSTRACT Objective Pathogenic variants in five established leptin‐melanocortin pathway genes (LEP, LEPR, MC4R, PCSK1, POMC) are associated with severe early‐onset obesity and are targets for emerging treatments. However, these variants are rare in these patients, suggesting the involvement of additional genes interacting with this pathway. Methods Next‐
Nathan Faccioli, Chrisitne Poitou, Mathieu Georget, Françoise Bertin, Ahlam Azar‐Kolakez, Claire Carette, Pauline Faucher, Blandine Gatta‐Cherifi, Julie Gonneau‐Lejeune, Agnès Linglart, Karine Clément, Johanne Le Beyec‐Le Bihan, Béatrice Dubern   +12 more
wiley   +1 more source

Differential seasonal performance of C3-epi-D3 level and proportion on multiple metabolic disorders in patients with type 2 diabetes mellitus. [PDF]

Eur J Med Res
Chen X, Peng B, Ye W, Wu B, Yang Q, Tang J, Yang Y.   +6 more
europepmc   +1 more source

Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial

Obesity, EarlyView.
ABSTRACT Objective This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).
Alejandro Campos, Wissam Ghusn, Lizeth Cifuentes, Daniel Sacoto, Sima Fansa, Diego Anazco, Maria L. Ricardo‐Silgado, Anas Hashem, Megan Schaefer, William S. Harmsen, Heather J. Gunn, Craig Peterson, Deborah Larsen, Santosh T. Varghese, Maria D. Hurtado, Andres Acosta   +15 more
wiley   +1 more source

Comparison of Risk Stratification Tools for Atherosclerotic Cardiovascular Disease and Cardiovascular-Kidney-Metabolic Syndrome in Primary Care. [PDF]

Med Sci (Basel)
Vázquez Martínez VH, Martínez Bautista H, Muñoz Villegas P, Loera Morales JI, Salazar MDRP.   +4 more
europepmc   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source